Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England https://www.medrxiv.org/content/10.1101/2022.11.28.22282808
Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England https://www.medrxiv.org/content/10.1101/2022.11.28.22282808